Abstract
Pfizer Inc is developing CP-751871, a fully human IgG2 antibody specific for the type I insulin-like growth factor receptor for the potential treatment of various cancers and rheumatoid arthritis. A phase Ib/II clinical trial of CP-751871 in combination with paclitaxel and carboplatin in patients with advanced NSCLC is underway.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 299-304 |
| Number of pages | 6 |
| Journal | Current Opinion in Molecular Therapeutics |
| Volume | 9 |
| Issue number | 3 |
| State | Published - Jun 2007 |
